ReviewJournal of Cancer2025
Predictive and Prognostic Biomarkers of Recurrence in Locoregional Colorectal Cancer.
Review in Journal of Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Extracellular vesicle and particle biomarkers in cancer: a machine learning blueprint for liquid biopsy.Journal of nanobiotechnology · 2026Review
- Multi-Omics and Clinical Data Analyses of Protein Arginine Methyltransferases in Pan-Cancer and Colorectal Cancer.International journal of medical sciences · 2026Article
- Dynamic monitoring of immunoglobulin G as a prognostic indicator after curative resection in high-risk stage II-III colorectal cancer: a retrospective cohort study.Frontiers in oncology · 2026Article
- NOS2/ARG1 axis and immune cell ratios as promising prognostic and predictive biomarkers for Cetuximab combined with chemotherapy in wt-KRAS human colorectal cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains a major global health challenge, as recurrence and metastasis continue to significantly impact patient survival and management, especially in cases of locoregional disease. In this regard, identifying reliable predictive and prognostic biomarkers is essential not only for improving therapeutic strategies but also for personalizing treatment plans and guiding post-treatment surveillance. This article comprehensively reviews histological, genetic, microRNA (miRNA), circulating tumor cell (CTC), and serological biomarkers, all of which are closely linked to recurrence and metastatic progression in locoregional CRC.On the one hand, histological markers, such as tumor budding and lymphovascular invasion, offer crucial prognostic insights regarding disease aggressiveness. On the other hand, genetic alterations, including mutations in KRAS, BRAF, and TP53 genes, serve as predictive indicators for therapeutic response as well as risk of recurrence. Moreover, specific miRNAs, such as miR-21, have emerged not only as diagnostic but also as prognostic tools due to their association with metastasis and chemoresistance. Furthermore, circulating tumor cells and cell-free DNA (cfDNA) released by tumors into the bloodstream represent non-invasive biomarkers that are useful for the early detection of micrometastatic disease and real-time monitoring of therapeutic efficacy. Additionally, serological markers, including carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9), continue to play key roles in the routine surveillance of CRC. Integrating these biomarkers into clinical practice thus holds significant potential to stratify patients at high risk of recurrence and guide personalized therapeutic approaches, ultimately improving outcomes for CRC patients. This review consolidates recent findings and underscores the ongoing need for further studies to validate these biomarkers across larger patient cohorts and various CRC stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.